# Supplement for Potential Test-Negative Case-Control Study Bias in Outbreak Settings: Application to Ebola vaccination in DRC

Carl A. B. Pearson<sup>1,2,\*</sup>

W. John Edmunds<sup>1</sup> Rosalind M. Eggo<sup>1</sup> Thomas J. Hladish<sup>3</sup>

<sup>1</sup>Department of Infectious Disease Epidemiology & Centre for Mathematical Modelling of Infectious Diseases London School of Hygiene & Tropical Medicine

<sup>2</sup>South African Centre for Epidemiological Modelling and Analysis Stellenbosch University

<sup>3</sup>Department of Biology & Emerging Pathogens Institute University of Florida

\*correspondence to: carl.pearson {at} lshtm.ac.uk

6 January, 2020

## Contents

$\mathbf{S1}$	Overview	3
$\mathbf{S2}$	Generalisation of Nomenclature	3
	S2.1 Model Diagram	4
	S2.2 Population Heterogeneity	5
	S2.3 Exposure, Protection, Infection, and Recruitment	5
	S2.4 Recruitment-Related Parameters	6
	S2.5 Summary Recruitment Categories	6
	S2.6 Expanded TNCC Intervention Efficacy Estimator	6
$\mathbf{S3}$	Efficacy Estimator Bias	7
	S3.1 Test-Positive Odds	7
	S3.2 Test-Negative Odds	9
	S3.3 Relaxing Assumption that Prevented Infections Remain Secondary Recruits	11
$\mathbf{S4}$	Total Estimator Bias & Limiting Scenarios	12
	S4.1 True efficacy, $E$ , limits $\ldots$	13
	S4.2 Participating fraction, $p_{\rm in}$ , limits	13
	S4.3 Secondary Case Recruitment, $p_t$ , limits $\ldots$	15
	S4.4 Lower Limit on Secondary Relative Recruiting, $\rho$	15
S5	Translation of Limits to Recruitment Constraints	15
	S5.1 Attempting to Limit Recruitment to Participants Only	15
	S5.2 Attempting to Limit to Primary Recruitment Only	25
$\mathbf{S6}$	Calculation of Coverage, $L$ , and Participation, $p_{in}$	36
	S6.1 Measures During Intervention Distribution	36
$\mathbf{S7}$	Alternative Scenario Translation	38

## <sup>1</sup> S1 Overview

A Test-Negative Case Control (TNCC) study has been proposed to evaluate a new EVD vaccine during the 2 ongoing EVD epidemic in Eastern Democratic Republic of Congo (DRC). The main text discussed a model 3 of such a study: we described a population of individuals i) who heterogeneously receive a study vaccine, ii) 4 some of whom subsequently exhibit symptoms of Ebola Virus Disease (EVD) or have contact with a known 5 EVD case, and thus iii) are identified by either self-reporting and contact-tracing processes as part of an 6 outbreak response, and finally iv) are tested for EVD, making them recruitable for a TNCC study of that 7 vaccine. Particularly, we explored the potential for bias due to route of recruitment into the study, and 8 due to heterogeneity in vaccine distribution. As we noted in the discussion, TNCC studies could be used to q evaluate other kinds interventions. 10

To support application of the model to other contexts, we use more general terms in this Supplement (Section S2). Using those terms, we provide derivations of equations quoted in the main text (Sections S3-S5), additional results (Section S6), and translate the model to another example (Section S7).

## <sup>14</sup> S2 Generalisation of Nomenclature

<sup>15</sup> We consider a generic *study intervention*. The study intervention is in addition to any other outbreak control <sup>16</sup> measures that might be ongoing. As in the main text, this study intervention is heterogeneously distributed <sup>17</sup> at an individual level, which we represent with participation status and intervention coverage. The TNCC <sup>18</sup> study goal is to determine the intervention efficacy.

The main text discusses self-reporting and contact-tracing as particular recruiting routes for EVD, which more generally are a random *primary* process and a reactive *secondary* process, respectively; we also use these qualifiers to distinguish the associated exposure processes to the pathogen of interest. For both routes, we still assume a highly sensitive and specific test for identifying infections with the target pathogen. For EVD, recruitment is symptom-related, but it does not have to be for all pathogens, so here we discuss intervention efficacy in terms of infection rather than disease.

<sup>25</sup> The key assumptions in this model are:

- exposure to the target pathogen is identical for all individuals
- if infected by exposure, the probability of detection by the primary process is identical for all individuals
- the rate of exposure to any other pathogens that could result in testing (and therefore recruitment) is the same for all individuals
- all secondary recruits associated with an initial primary case have the same participation status as that primary case
- the secondary transmission and recruitment process is identical for all individuals

## <sup>33</sup> S2.1 Model Diagram




Figure S1: Model Diagram. This diagram illustrates the conceptual model of the population and recruitment process, showing: how the intervention might be distributed in the population (panel (a)), with the corresponding intervention term definitions for *participating fraction*,  $p_{in}$ , and *intervention coverage*, L (panel (b)); and how the primary process proceeds by finding an expected number of test-negatives, B, until finding a test-positive case, which initiates the secondary process leading to an expected number of additional tests,  $\lambda$ , of which R'' are expected to be test-positive in the absence of the study intervention (panel (c)), with the corresponding to summary categories of different routes to recruitment into the study (panel (d)).

## <sup>34</sup> S2.2 Population Heterogeneity

<sup>35</sup> There are two types of individuals in the population: *non-participating* and *participating*. Non-participating

<sup>36</sup> individuals do not receive the study intervention. Participating individuals randomly receive the intervention

<sup>37</sup> with some probability. Aside from participation and vaccination status, individuals are identical: they have

the same exposure risk for the target pathogen, same primary testing rate given exposure and non-exposure,

<sup>39</sup> and same secondary distribution and probability of exposing those individuals.

40 In the equations that follow, we label counts of individuals corresponding to their participation and inter-

- vention status. The totals of these categories determine the population heterogeneity characteristics. Total
   numbers are:
- $_{43}$  V, the number of participating individuals that received the intervention
- $_{44}$  U, the number of participating individuals that did not receive the intervention
- 45 C, of the recruitable population, those that are participating; C = V + U
- $_{46}$  N, individuals that did not participate
- 47 T, total potentially recruitable study population; T = C + N
- 48  $p_{in}$ , the participating fraction for the study,  $p_{in} = \frac{C}{T}$ ; used as participation probability for individuals
- 49 L, the intervention coverage in the participating population,  $L = \frac{V}{C}$ ; used as the probability participating 50 individuals have the intervention

## <sup>51</sup> S2.3 Exposure, Protection, Infection, and Recruitment

<sup>52</sup> During the outbreak, individuals  $\{V, U, N\}$  are potentially exposed and tested, and thus recruited in the <sup>53</sup> study, via two routes: i) the primary route, where individuals are exposed and tested randomly, independent <sup>54</sup> of any association with an identified case; ii) the secondary route, where individuals are exposed by and <sup>55</sup> tested because of connection with an identified case.

Test-positive individuals found by the primary process and those they associate with as detect by the secondary process have the same participation status in the model. Therefore primary test-positives from the participating population only interact via the secondary process with other participating individuals, and likewise for non-participating primary test-positives.

Relative to transmission of the target pathogen, all infections discovered by secondary route are assumed to result from exposures due to the associated primary case. Primary cases are assumed to result from a random exposure process (*i.e.* exposing individuals of the different types according to the relative proportions in the population).

All exposures result in infections, unless protected by the study intervention; potential infections prevented
 by other outbreak response measures (which benefit all individuals in the study population equally) are
 assumed to not be exposures in the context of the model. For both primary and secondary exposures, an

<sup>67</sup> individual that has received the intervention may avoid infection with probability corresponding to the study
 <sup>68</sup> intervention efficacy. Exposed individuals who have not received the intervention become infected.

The intervention is also assumed to have no impact on infections that are not by the target pathogen, even where those infections could lead to a test. Finally, neither process is assumed to observe all of the relevant  $_{71}$  events (*i.e.*, those that lead to primary or secondary recruitment) that occur, just that observation rates do  $_{72}$  not differ by participation status.

## 73 S2.4 Recruitment-Related Parameters

These real-world infection and testing processes are stochastic, and we consider the asymptotic expected (*i.e.*, average) outcomes of these processes. We define the following set of parameters corresponding to expected counts of recruitment-related events per primary test-positive, and the probability of preventing infection.

- $^{78}$  B + 1: the expected number of tests from the primary process required to find a single test-positive case; *i.e.*,
- on average, for B + 1 individuals tested via primary route, B are test-negative and 1 is test-positive.
- $\lambda$ : the expected number of tests from the secondary process, for each case identified by the primary process.
- R'': the expected number of test-positives in the contacts of identified cases when there is no intervention.

*E*: the intervention efficacy; *i.e.*, the probability that an individual who has received the intervention will avoid infection when exposed (relative to an individual without the intervention) either via the primary or secondary routes

## <sup>85</sup> S2.5 Summary Recruitment Categories

<sup>86</sup> In addition to the participation and intervention states, we denote individuals by their routes to testing <sup>87</sup> and test outcomes, with super- and subscripts respectively. These are summarized earlier in Fig. S1, and as <sup>88</sup> follows:

- <sup>89</sup>  $C'_{+}=V'_{+}+U'_{+}$ : among corresponding individuals: testing positive, recruited via primary process
- <sup>90</sup>  $C''_{+} = V''_{+} + U''_{+}$  from corresponding populations, testing positive, recruited via secondary process
- $T'_{-}, N'_{-}$ : from corresponding populations, testing negative, recruited via primary process  $C' = V'_{-} + U'_{-}$ :
- $C''_{-} = V''_{-} = V''_{-} = V''_{-}$  from corresponding populations, testing negative, recruited via secondary process

## <sup>93</sup> S2.6 Expanded TNCC Intervention Efficacy Estimator

<sup>94</sup> The conventional TNCC efficacy estimator stratifies the recruited population into four groups, made from

<sup>95</sup> two binary distinctions: received the intervention versus not, and test-positive for the pathogen of interest

<sup>96</sup> versus test-negative. That efficacy estimator is:

$$\begin{array}{l} \text{estimated} \\ \text{efficacy} \end{array} = 1 - \frac{\# \text{ intervention, test-positive}}{\# \text{ non-intervention, test-negative}} \times \frac{\# \text{ non-intervention, test-negative}}{\# \text{ intervention, test-negative}} \end{array}$$

<sup>97</sup> In terms of the types of individuals defined at the end of Section S2.3, this equation becomes:

$$\hat{E} = 1 - \frac{V'_{+} + V''_{+}}{N'_{+} + N''_{+} + U'_{+} + U''_{+}} \times \frac{N'_{-} + U'_{-} + N''_{-} + U''_{-}}{V'_{-} + V''_{-}}$$
(S1)

which can be thought of as two odds of having received the intervention, each conditional on the two possible
 test outcomes. We will refer to these as the test-positive odds and the test-negative odds.

## <sup>100</sup> S3 Efficacy Estimator Bias

<sup>101</sup> To determine the potential bias of  $\hat{E}$  for a TNCC study in an outbreak setting, we need to translate Eq. S1 <sup>102</sup> from being in terms of total individual counts, into the expected totals, given the study target intervention <sup>103</sup> and outbreak conditions. We will examine each of the two odds terms in turn, then combine the results.

## <sup>104</sup> S3.1 Test-Positive Odds

Starting with the test-positive odds term, we first factorise (by  $C'_+$ , or  $N'_+$ ), such that most terms are expressed as proportions:

$$\frac{V'_{+} + V''_{+}}{N'_{+} + N''_{+} + U'_{+} + U''_{+}} = \frac{C'_{+} \left(\frac{V'_{+}}{C'_{+}} + \frac{V''_{+}}{C'_{+}}\right)}{N'_{+} \left(1 + \frac{N''_{+}}{N'_{+}}\right) + C'_{+} \left(\frac{U'_{+}}{C'_{+}} + \frac{U''_{+}}{C'_{+}}\right)}$$
(S2)

Recall we defined R'' as the expected number of cases that would be found via the secondary route among 107 individuals that had not received the study intervention (*i.e.*, non-participating individuals or individuals outside of the recruitable population). The proportion  $\frac{N_{+}^{\prime\prime}}{N_{+}^{\prime}}$  is total number of secondary cases over the 108 109 total number of primary cases (among non-participating individuals), which is also the average number of 110 secondary cases per primary case, so we can substitute  $R'' = \frac{N''_+}{N'_-}$ . Since we have restricted the study to a 111 scenario where only a single primary case exposes secondary cases, there is neither indirect protection or 112 force of infection from multiple sources. Thus, amongst participating individuals (*i.e.* those in C), R'' will 113 be reduced on average by the probability that exposed individuals are intervention recipients and protected. 114 This probability is equal to coverage, L, multiplied by the efficacy, E. Therefore,  $\frac{C''_+}{C'} = R''(1 - LE)$  in the 115 participating population. 116

<sup>117</sup> Using these substitutions and introducing some identity multipliers,  $1 = \frac{C_{+}''}{C_{+}''}$ , we can rewrite Eq. S2 as:

$$\frac{C'_{+}\left(\frac{V'_{+}}{C'_{+}} + \frac{C''_{+}}{C''_{+}}\frac{V''_{+}}{C''_{+}}\right)}{N'_{+}\left(1 + \frac{N''_{+}}{N'_{+}}\right) + C'_{+}\left(\frac{U'_{+}}{C'_{+}} + \frac{C''_{+}}{C''_{+}}\frac{U''_{+}}{C'_{+}}\right)} = \frac{C'_{+}\left(\frac{V'_{+}}{C'_{+}} + \frac{V''_{+}}{C''_{+}}R''(1 - LE)\right)}{N'_{+}\left(1 + R''\right) + C'_{+}\left(\frac{U'_{+}}{C'_{+}} + \frac{U''_{+}}{C''_{+}}R''(1 - LE)\right)}$$
(S3)

<sup>118</sup> Next, we show how the proportions between the counts of the participating individuals can be substituted <sup>119</sup> to express the odds in terms of model parameters. Starting with  $\frac{V'_{\pm}}{C'_{\pm}}$ : this is the probability of an individual <sup>120</sup> receiving the intervention, conditional on there being an initial infection in the participating population. <sup>121</sup> Though the exposure probabilities are the same between participating and non-participating populations, if <sup>122</sup> LE > 0, the probability that an exposure results in an infection is lower. Given an exposure event:

$$\frac{V'_{+}}{C'_{+}} = P(\text{received intervention} \mid \text{is infected & participating}) = P(i \in V \mid +, i \in C)$$
$$= \frac{P(+|i \in V) \times P(i \in V \mid i \in C)}{P(+|i \in C)} = \frac{(1-E) \times L}{(1-L) + L(1-E)} = \frac{(1-E)L}{1-LE}$$

<sup>123</sup> We can use the same logic for the secondary exposures: conditional on a secondary exposure that could

result in infection, the same relationship applies. To solve for  $\frac{U'_+}{C'_+}$ , we take the complements. Therefore, these four ratios are:

$$\frac{V'_{+}}{C'_{+}} = \frac{V''_{+}}{C''_{+}} = \frac{(1-E)L}{1-LE} 
\frac{U'_{+}}{C'_{+}} = \frac{U''_{+}}{C''_{+}} = \frac{1-L}{1-LE}$$
(S4)

<sup>126</sup> which means we can further substitute in Eq. S3:

$$\frac{C'_{+}\left(\frac{V'_{+}}{C'_{+}} + \frac{V''_{+}}{C''_{+}}R''(1-LE)\right)}{N'_{+}\left(1+R''\right) + C'_{+}\left(\frac{U'_{+}}{C'_{+}} + \frac{U''_{+}}{C''_{+}}R''(1-LE)\right)}{\sum_{i=1}^{N'_{+}}\left(1+R''_{+}\right) + C'_{+}\frac{U'_{+}}{C'_{+}}\left(1+R''(1-LE)\right)} = \frac{C'_{+}\frac{(1-E)L}{1-LE}\left(1+R''(1-LE)\right)}{N'_{+}\left(1+R''\right) + C'_{+}\frac{1-L}{1-LE}\left(1+R''(1-LE)\right)} = \frac{C'_{+}\frac{(1-E)L}{1-LE}\left(1+R''(1-LE)\right)}{\sum_{i=1}^{N'_{+}}\frac{(1-E)L}{1-LE}\left(1+R''(1-LE)\right)}$$
(S5)

Like for determining the fraction of infections in participating individuals that did or did not receive the intervention (Eq. S3.1), we can also use Bayes Theorem to find the relative fractions of infections that occurred in individuals that did or did not participate,  $\frac{C'_{+}}{T'_{+}}$  and  $\frac{N'_{+}}{T'_{+}}$ :

130 which means that,

$$\frac{\frac{C'_{+}(1-E)L}{T'_{+}(1-LE)}}{\frac{N'_{+}(1+R'')}{T'_{+}(1-LE)} + \frac{C'_{+}}{T'_{+}(1-LE)}} = \frac{1-LEp_{\rm in}}{1-LEp_{\rm in}} \frac{(1-LE)p_{\rm in}\frac{(1-E)L}{1-LE}}{(1-p_{\rm in})\frac{(1+R'')}{1+R''(1-LE)} + (1-LE)p_{\rm in}\frac{1-L}{1-LE}} = \frac{p_{\rm in}(1-E)L}{(1-p_{\rm in})\frac{(1+R'')}{1+R''(1-LE)} + p_{\rm in}(1-L)}$$
(S7)

131 and therefore,

$$\frac{V'_{+} + V_{+}}{N'_{+} + N_{+} + U'_{+} + U_{+}} = \frac{p_{\rm in}(1-E)L}{(1-p_{\rm in})\frac{(1+R'')}{1+R''(1-LE)} + p_{\rm in}(1-L)}$$
(S8)

<sup>132</sup> In conventional TNCC studies there is no secondary recruitment. If secondary recruitment were eliminated <sup>133</sup> under outbreak circumstances, that would imply that  $\lambda \to 0$ , which also means that  $R'' \to 0$ . During <sup>134</sup> outbreaks, the secondary process would still occur as part of the response (*i.e.* there would both testing and <sup>135</sup> case-finding), but the people identified would not be recruited. Under that limit:

$$\lim_{R'' \to 0} \frac{1 + R''}{1 + R''(1 - LE)} = 1$$
$$\lim_{R'' \to 0} \frac{Lp_{\rm in}(1 - E)}{(1 - p_{\rm in}) \frac{1 + R''}{1 + R''(1 - LE)} + p_{\rm in} - Lp_{\rm in}} = \frac{Lp_{\rm in}(1 - E)}{1 - Lp_{\rm in}}$$
(S9)

which suggests a useful re-arrangement of the final form of the test-positive odds, so it has a clear separation of the terms which appear in the unbiased estimator (*i.e.* primary recruiting only) and the remaining factors:

$$\frac{Lp_{\rm in}(1-E)}{(1-p_{\rm in})\frac{1+R''}{1+R''(1-LE)} + p_{\rm in}(1-L)} = \frac{Lp_{\rm in}(1-E)}{(1-p_{\rm in})\frac{1+R''}{1+R''(1-LE)} + p_{\rm in} - Lp_{\rm in} + 1-1}$$
obtain 1 - Lp<sub>in</sub> term to factor out... = 
$$\frac{Lp_{\rm in}(1-E)}{(1-p_{\rm in})\frac{1+R''}{1+R''(1-LE)} - (1-p_{\rm in}) + (1-Lp_{\rm in})}$$
factor other term... = 
$$\frac{Lp_{\rm in}(1-E)}{(1-Lp_{\rm in}) + (1-p_{\rm in})\left(\frac{1+R''}{1+R''(1-LE)} - 1\right)}$$
simplify other term... = 
$$\frac{Lp_{\rm in}(1-E)}{(1-Lp_{\rm in}) + (1-p_{\rm in})\left(\frac{LER''}{1+R''(1-LE)}\right)}$$
factor out target terms... = 
$$\frac{Lp_{\rm in}(1-E)}{1-Lp_{\rm in}}\left[1 + \frac{ER''}{1+R''(1-LE)}\frac{L(1-p_{\rm in})}{1-Lp_{\rm in}}\right]^{-1}$$
(S10)

In Eq. S10, we now have only terms that describe the intervention (participation and coverage probabilities,  $p_{in}$  and L, and efficacy E) and epidemiology (R'').

## <sup>141</sup> S3.2 Test-Negative Odds

We assume that the testing criteria for the secondary process is not affected by the presence of the intervention. For example, a contact-tracing-related criteria might be principally about high-risk interactions rather than particular symptoms, or the symptom threshold might be sufficiently relaxed that almost all contacts meet it. Similarly, a purely geographical criteria would be unaffected by presence or absence of the intervention. Thus, in our model all the prevented secondary infections (via intervention efficacy E) are still recruited by the secondary process as test-negatives. This is a bounding assumption; see the end of this section for relaxing this assumption.

<sup>149</sup> Turning to the test-negative odds, we first replace the primary test-negatives by the contribution from B, <sup>150</sup> the average number of test-negatives per test-positive via the primary route. Given that definition, the total <sup>151</sup> number of primary test-negatives is  $T'_{-} = BT'_{+}$ . Because the intervention has no effect on the causes that lead <sup>152</sup> to testing negative via the primary route, the representation of individuals follows their proportions in the <sup>153</sup> population:

$$\frac{N'_{-} + U'_{-} + N''_{-} + U''_{-}}{V'_{-} + V''_{-}} = \frac{BT'_{+}(1 - Lp_{\rm in}) + N''_{-} + U''_{-}}{BT'_{+}Lp_{\rm in} + V''_{-}}$$
(S11)

As with the test-positives odds, we can factorise and introduce identity multiples to re-arrange into terms that we can then use Bayes Theorem to replace with model parameters:

$$\frac{BT'_{+}(1-Lp_{\rm in})+N''_{-}+U''_{-}}{BT'_{+}Lp_{\rm in}+V''_{-}} = \frac{B(1-Lp_{\rm in})+\frac{1}{T'_{+}}(N''_{-}+U''_{-})}{BLp_{\rm in}+\frac{V''_{-}}{T'_{+}}}$$
$$= \frac{B(1-Lp_{\rm in})+\left(\frac{N'_{+}}{T'_{+}}\frac{N''_{-}}{N'_{+}}+\frac{C'_{+}}{T'_{+}}\frac{U''_{-}}{C'_{+}}\right)}{BLp_{\rm in}+\frac{C'_{+}}{T'_{+}}\frac{V''_{-}}{C'_{+}}}$$
(S12)

<sup>156</sup> We can use the participating and non-participating fractions of primary test-positives,  $\frac{C'_+}{T'_+}$  and  $\frac{N'_+}{T'_+}$ , from <sup>157</sup> refactoring the test-positive odds (Eq. S6).

Amongst non-participating individuals, on average  $\lambda - R''$  of recruits from the secondary route will be testnegative. This means that  $\frac{N''_{-}}{N'_{+}} = \lambda - R''$ .

This definition also implies that the exposed proportion is  $p_t = \frac{R''}{\lambda}$  because R'' individuals are infected per  $\lambda$ secondary individuals. The complementary non-exposed proportion is therefore  $1 - p_t = \frac{\lambda - R''}{\lambda}$ . This value is like a transmission probability, though that interpretation should be used with caution: the denominator is determined by the secondary observation process, and thus the proportion may not clearly translate to the biological process probability.

Also by definition, amongst participating individuals, only 1 - LE of the exposed individuals are infected, therefore:

$$\frac{C''_{-}}{C'_{+}} = (1 - p_t(1 - LE))\lambda = \lambda - R''(1 - LE)$$

<sup>165</sup> We again use Bayes Theorem to translate these ratios into model parameter expressions.

$$\frac{U''_{-}}{C''_{-}} = P(\text{is unvaccinated } | \text{ is not infected & participating}) = P(i \in U|-, i \in C) = \frac{P(-|i \in U)P(i \in U|i \in C)}{P(-|i \in C)} \\
= \frac{\frac{\lambda - R''}{\lambda}(1 - L)}{\frac{\lambda - R''}{\lambda}(1 - L) + L\left(\frac{\lambda - R''}{\lambda} + \frac{R''}{\lambda}E\right)} = \frac{(\lambda - R'')(1 - L)}{\lambda - R''(1 - LE)} \\
\frac{V''_{-}}{C''_{-}} = 1 - P(i \in U|-, i \in C) = \frac{(\lambda - (1 - E)R'')L}{\lambda - (1 - LE)R''} \\
\frac{U''_{-}}{C''_{+}} = \frac{U''_{-}}{C''_{-}}\frac{C''_{-}}{C'_{+}} = (\lambda - R'')(1 - L) \\
\frac{V''_{-}}{C''_{+}} = (\lambda - (1 - E)R'')L$$
(S13)

<sup>166</sup> Substituting these into the for the appropriate ratios, we obtain:

$$\frac{B(1-Lp_{\rm in}) + \left(\frac{N'_{+}}{T'_{+}}\frac{N_{-}}{N'_{+}} + \frac{C'_{+}}{T'_{+}}\frac{U_{-}}{C'_{+}}\right)}{BLp_{\rm in} + \frac{C'_{+}}{T'_{+}}\frac{V_{-}}{C'_{+}}} = \frac{B(1-Lp_{\rm in}) + \left(\frac{1-p_{\rm in}}{1-LEp_{\rm in}}(\lambda-R'') + \frac{(1-LE)p_{\rm in}}{1-LEp_{\rm in}}(\lambda-R'')(1-L)\right)}{BLp_{\rm in} + \frac{(1-LE)p_{\rm in}}{1-LEp_{\rm in}}(\lambda-(1-E)R'')L}$$

$$\frac{N'_{-} + U'_{-} + N_{-} + U_{-}}{V'_{-} + V_{-}} = \frac{B(1-Lp_{\rm in}) + \left(1-Lp_{\rm in}\frac{1-LE}{1-LEp_{\rm in}}\right)(\lambda-R'')}{BLp_{\rm in} + Lp_{\rm in}\frac{1-LE}{1-LEp_{\rm in}}(\lambda-R'' + ER'')}$$
(S14)

As in Section S3.1, for the conventional TNCC assumptions,  $\lambda \to 0$  and  $R'' \to 0$ . Again, it is not that the secondary process ceases, but just that recruitment via that route is disallowed. Enforcing those constraints:

$$\lim_{\lambda \to 0} \frac{B(1 - Lp_{\rm in}) + \left(1 - Lp_{\rm in}\frac{1 - LE}{1 - LEp_{\rm in}}\right)(\lambda - R'')}{BLp_{\rm in} + Lp_{\rm in}\frac{1 - LE}{1 - LEp_{\rm in}}(\lambda - R'' + ER'')} = \frac{B(1 - Lp_{\rm in}) + \left(1 - Lp_{\rm in}\frac{1 - LE}{1 - LEp_{\rm in}}\right)0}{BLp_{\rm in} + Lp_{\rm in}\frac{1 - LE}{1 - LEp_{\rm in}}0} = \frac{1 - Lp_{\rm in}}{Lp_{\rm in}}$$
(S15)

<sup>170</sup> As with test-positives odds, we can refactor in terms of the conventional TNCC limit:

$$\frac{B(1 - Lp_{in}) + \left(1 - Lp_{in}\frac{1 - LE}{1 - LEp_{in}}\right)(\lambda - R'')}{BLp_{in} + Lp_{in}\frac{1 - LE}{1 - LEp_{in}}(\lambda - R'' + ER'')} = \frac{1 - Lp_{in}}{Lp_{in}}\frac{B + \frac{1 - Lp_{in}\frac{1 - LE}{1 - LEp_{in}}}{(1 - LEp_{in})}(\lambda - R'')}{B + \frac{1 - LE}{1 - LEp_{in}}(\lambda - R'' + ER'')} \\
= \frac{1 - Lp_{in}}{Lp_{in}}\frac{B + \frac{1 - LEp_{in} - Lp_{in}(1 - LE)}{(1 - Lp_{in})(1 - LEp_{in})}(\lambda - R'')}{B + \frac{1 - LE}{1 - LEp_{in}}(\lambda - R'' + ER'')} \\
= \frac{1 - Lp_{in}}{Lp_{in}}\frac{B + \frac{1 - Lep_{in} - Lp_{in}(1 - LE)}{(1 - Lp_{in} - LEp_{in})}(\lambda - R'')}{B + \frac{1 - LE}{1 - LEp_{in}}(\lambda - R'' + ER'')} \tag{S16}$$

In Eq. S16, we now have only terms that describe the intervention  $(p_{in}, L, and E)$  and epidemiology  $(R'', \lambda, and B)$ . Note that this term includes more of the model parameters than the test-positive odds (Eq. S10).

# S3.3 Relaxing Assumption that Prevented Infections Remain Secondary Recruits

Earlier, we assumed that the secondary recruitment process was unperturbed by the study intervention. For a secondary process that is, for example, purely geographical because it concerns a pathogen that is highly asymptomatic (*e.g.*, neighbor-household testing for dengue), this assumption is consistent. Where it becomes less clearly acceptable as a simplification, is if there remains some disease- or symptom-based component to secondary recruitment.

<sup>181</sup> In the main text, we focus on a vaccine study for EVD, where the primary process was self-reporting <sup>182</sup> with multiple EVD-like symptoms leading to testing. The secondary process is nominally contact-tracing <sup>183</sup> combined with a high-fever. We assumed that high-fever would almost always be present for the contacts <sup>184</sup> that avoided EVD infection because of the vaccine. In reality there would be some attack rate less than <sup>185</sup> 100%.

<sup>186</sup> If we define the proportion of people meeting a symptom-based component of the secondary process as  $\alpha$ <sup>187</sup> and ignore the zero-bias term (Eq. S15) as a coefficient, then Eq. S16 becomes:

test-negative odds 
$$\propto \frac{B + \frac{1 - Lp_{\text{in}} - L^2 Ep_{\text{in}}}{1 - Lp_{\text{in}} - L^2 Ep_{\text{in}}^2} (\lambda - R'')}{B + \frac{1 - LE}{1 - LE p_{\text{in}}} (\lambda - R'' + E\alpha R'')}$$
(S17)

That is, of all the potential secondary recruits that could be added to test-negatives due to prevention of infection, only some exhibit the additional criteria. Note that there is no impact of relaxing this assumption on the test-positive odds.

If  $\alpha \to 1$ , *i.e.* everyone meets this extra criteria, we get Eq. S16. As  $\alpha \to 0$ , the denominator decreases, increasing the test-negative odds overall, and in turn reducing the estimated efficacy. When  $\alpha = 0$ :

test-negative odds 
$$\propto \frac{B + \frac{1-Lp_{\rm in} - LEp_{\rm in} + L^2 Ep_{\rm in}}{1-Lp_{\rm in} - LEp_{\rm in} + L^2 Ep_{\rm in}^2} (\lambda - R'')}{B + \frac{1-LE}{1-LEp_{\rm in}} (\lambda - R'')}$$
(S18)

<sup>193</sup> In the case of  $p_{\rm in} = 1$ , this reduces to unity. More generally,

$$Lp_{\rm in} \leq L \implies 1 - Lp_{\rm in} \geq 1 - L \implies \frac{1 - L}{1 - Lp_{\rm in}} \leq 1$$
  

$$\implies 1 \geq p_{\rm in} \frac{1 - L}{1 - Lp_{\rm in}} \implies LE \geq LEp_{\rm in} \frac{1 - L}{1 - Lp_{\rm in}}$$
  

$$\implies 1 - LE \leq 1 - LEp_{\rm in} \frac{1 - L}{1 - Lp_{\rm in}} \implies 1 - LE \leq \frac{1 - Lp_{\rm in} - LEp_{\rm in} - L^2Ep_{\rm in}}{1 - Lp_{\rm in}}$$
  

$$\implies \frac{1 - LE}{1 - LEp_{\rm in}} \leq \frac{1 - Lp_{\rm in} - LEp_{\rm in} - L^2Ep_{\rm in}}{(1 - LEp_{\rm in})(1 - Lp_{\rm in})}$$
  

$$\implies B + \frac{1 - LE}{1 - LEp_{\rm in}} (\lambda - R'') \leq B + \frac{1 - Lp_{\rm in} - LEp_{\rm in} - L^2Ep_{\rm in}}{(1 - LEp_{\rm in})(1 - Lp_{\rm in})} (\lambda - R'')$$
  

$$\implies 1 \leq \frac{B + \frac{1 - Lp_{\rm in} - LEp_{\rm in} - L^2Ep_{\rm in}}{(1 - LEp_{\rm in})(1 - Lp_{\rm in})} (\lambda - R'')}$$
(S19)

<sup>194</sup> This means that without any contribution from  $\alpha$ , test-negative odds biases increasingly towards underesti-

mation as participation decreases. As  $\alpha \rightarrow 1$ , this effect is counteracted, but can in turn lead to overestimation of efficacy.

## <sup>197</sup> S4 Total Estimator Bias & Limiting Scenarios

<sup>198</sup> Combining the test-positives odds and test-negatives odds:

$$\hat{E} = 1 - \frac{V'_{+} + V''_{+}}{N'_{+} + N''_{+} + U'_{+} + U''_{+}} \frac{N'_{-} + U'_{-} + N''_{-} + U''_{-}}{V'_{-} + V''_{-}}$$

$$= 1 - \frac{Lp_{in}(1-E)}{1-Lp_{in}} \left[ 1 + \frac{ER''}{1+R''(1-LE)} \frac{L(1-p_{in})}{1-Lp_{in}} \right]^{-1} \frac{1-Lp_{in}}{Lp_{in}} \frac{B + \frac{1-Lp_{in}-LEp_{in}+L^{2}Ep_{in}^{2}}{B + \frac{1-LE}{1-LEp_{in}}(\lambda - R'' + ER'')}$$

$$= 1 - (1-E) \left[ 1 + \frac{ER''}{1+R''(1-LE)} \frac{L(1-p_{in})}{1-Lp_{in}} \right]^{-1} \frac{B + \frac{1-Lp_{in}-LEp_{in}+L^{2}Ep_{in}}{B + \frac{1-Lp_{in}-LEp_{in}+L^{2}Ep_{in}^{2}}{(\lambda - R'')} \frac{(\lambda - R'')}{B + \frac{1-LE}{1-LEp_{in}}(\lambda - R'' + ER'')}$$
(S20)

<sup>199</sup> This suggests a different factorization:

$$\hat{E} = 1 - (1 - E) \left[ 1 + \frac{E \frac{R''}{\lambda} \frac{\lambda}{B+1} (B+1)}{1 + \frac{R''}{\lambda} \frac{\lambda}{B+1} (B+1) (1 - LE)} \frac{L(1 - p_{\rm in})}{1 - Lp_{\rm in}} \right]^{-1} \frac{1 + \frac{1 - Lp_{\rm in} - LE p_{\rm in} + L^2 E p_{\rm in}}{1 - Lp_{\rm in} - LE p_{\rm in} + L^2 E p_{\rm in}^2} \frac{\lambda}{B+1} \frac{B+1}{B} \left( 1 - \frac{R''}{\lambda} \right) \frac{L(1 - p_{\rm in})}{1 - Lp_{\rm in}} \left[ 1 - \frac{LE}{1 - LE p_{\rm in}} \frac{\lambda}{B+1} \frac{B+1}{B} \left( 1 - \frac{R''}{\lambda} + E \frac{R''}{\lambda} \right) \right]^{-1} \frac{1 - LE}{1 - LE p_{\rm in}} \frac{\lambda}{B+1} \frac{B+1}{B} \left( 1 - \frac{R''}{\lambda} + E \frac{R''}{\lambda} \right) \frac{R}{B+1} \frac{R}{B} \left( 1 - \frac{R''}{\lambda} + E \frac{R''}{\lambda} \right) \frac{R}{B+1} \frac{R}{B} \left( 1 - \frac{R''}{\lambda} + E \frac{R''}{\lambda} \right) \frac{R}{B+1} \frac{R}{B} \left( 1 - \frac{R''}{\lambda} + E \frac{R''}{\lambda} \right) \frac{R}{B+1} \frac{R}{B} \left( 1 - \frac{R''}{\lambda} + E \frac{R''}{\lambda} \right) \frac{R}{B+1} \frac{R}{B} \left( 1 - \frac{R''}{\lambda} + E \frac{R''}{\lambda} \right) \frac{R}{B+1} \frac{R}{B} \left( 1 - \frac{R''}{\lambda} + E \frac{R''}{\lambda} \right) \frac{R}{B+1} \frac{R}{B} \left( 1 - \frac{R''}{\lambda} + E \frac{R''}{\lambda} \right) \frac{R}{B+1} \frac{R}{B} \left( 1 - \frac{R''}{\lambda} + E \frac{R''}{\lambda} \right) \frac{R}{B+1} \frac{R}{B} \left( 1 - \frac{R''}{\lambda} + E \frac{R''}{\lambda} \right) \frac{R}{B+1} \frac{R}{B} \left( 1 - \frac{R''}{\lambda} + E \frac{R}{B} \right) \frac{R}{B+1} \frac{R}{B} \left( 1 - \frac{R''}{\lambda} + E \frac{R}{B} \right) \frac{R}{B+1} \frac{R}{B} \frac{R}{B+1} \frac{R}{B} \left( 1 - \frac{R}{B} \right) \frac{R}{B+1} \frac{R}{B} \frac{R}{B} \frac{R}{B+1} \frac{R}{B} \frac{$$

We can define secondary test-positive fraction,  $p_t = \frac{R''}{\lambda}$ , the negative proportion of primary alerts,  $f_- = \frac{B}{B+1}$ , and relative rate of secondary recruitment to primary recruitment,  $\rho = \frac{\lambda}{B+1}$ . Noting that  $B + 1 = (1 - f_-)^{-1}$ This yields:

$$\hat{E} = 1 - (1 - E) \left[ 1 + \frac{E \frac{p_t \rho}{1 - f_-}}{1 + \frac{p_t \rho}{1 - f_-} (1 - LE)} \frac{L(1 - p_{\rm in})}{1 - Lp_{\rm in}} \right]^{-1} \frac{1 + \frac{1 - Lp_{\rm in} - LE p_{\rm in} + L^2 E p_{\rm in}^2}{1 - Lp_{\rm in} - LE p_{\rm in} + L^2 E p_{\rm in}^2} \frac{\rho}{f_-} (1 - p_t)}{1 + \frac{1 - LE}{1 - LE p_{\rm in}} \frac{\rho}{f_-} (1 - p_t(1 - E))}$$
(S22)

We use this framing for all the main text results. This formulation highlights the important relative values within the model, while still maintaining terms that can be reasoned about and potentially measured. In this framing  $\hat{E}$  is still a function of six variables, *i.e.*  $\{E, L, p_{\rm in}, R'', \lambda, B\}$  versus  $\{E, L, p_{\rm in}, p_t, \rho, f_-\}$ .

In the following subsections, we show limiting conditions for the estimator with respect to the assorted parameters.

## $_{208}$ S4.1 True efficacy, E, limits

As the intervention tends toward either doing nothing  $(E \rightarrow 0)$  or perfect protection  $(E \rightarrow 1)$ , the estimator bias tends to vanish.

$$\lim_{E \to 0} \hat{E} = 1 - [1]^{-1} \frac{1 + \frac{1 - Lp_{\text{in}}}{1 - Lp_{\text{in}}} \frac{\rho}{f_{-}} (1 - p_{t})}{1 + \frac{\rho}{f_{-}} (1 - p_{t})} = 1 - 1 = 0$$

$$\lim_{E \to 1} \hat{E} = 1 - 0 (\dots) = 1$$
(S23)

## <sup>211</sup> S4.2 Participating fraction, $p_{in}$ , limits

$$\begin{split} \lim_{p_{in}\to 0} \hat{E} &= 1 - \left(1 - E\right) \left[ 1 + \frac{LE \frac{p_{t}\rho}{1 - f_{-}}}{1 + \frac{p_{t}\rho}{1 - f_{-}} \left(1 - LE\right)} \right]^{-1} \frac{1 + \frac{1}{1} \frac{\rho}{f_{-}} \left(1 - p_{t}\right)}{1 + \frac{1 - LE}{p_{-}} \frac{\rho}{f_{-}} \left(1 - p_{t}\right)} \\ &= 1 - \left(1 - E\right) \left[ \frac{1 + \frac{p_{t}\rho}{1 - f_{-}} \left(1 - LE\right)}{1 + \frac{p_{t}\rho}{1 - f_{-}} \left(1 - LE\right)} + \frac{LE \frac{p_{t}\rho}{1 - f_{-}}}{1 + \frac{p_{t}\rho}{1 - f_{-}} \left(1 - LE\right)} \right]^{-1} \frac{1 + \frac{\rho}{f_{-}} \left(1 - p_{t}\right)}{1 + \left(1 - LE\right) \frac{\rho}{f_{-}} \left(1 - p_{t} \left(1 - E\right)\right)} \\ &= 1 - \left(1 - E\right) \left[ \frac{1 + \frac{p_{t}\rho}{1 - f_{-}}}{1 + \frac{p_{t}\rho}{1 - f_{-}} \left(1 - LE\right)} \right]^{-1} \frac{1 + \frac{\rho}{f_{-}} \left(1 - p_{t}\right)}{1 + \left(1 - LE\right) \frac{\rho}{f_{-}} \left(1 - p_{t} \left(1 - E\right)\right)} \\ &= 1 - \left(1 - E\right) \left[ \frac{1 + \frac{p_{t}\rho}{1 - f_{-}}}{1 + \frac{p_{t}\rho}{1 - f_{-}} \left(1 - LE\right)} \right]^{-1} \frac{1 + \frac{\rho}{f_{-}} \left(1 - p_{t}\right)}{1 + \left(1 - LE\right) \frac{\rho}{f_{-}} \left(1 - p_{t} \left(1 - E\right)\right)} \\ &= 1 - \left(1 - E\right) \frac{1 + \frac{p_{t}\rho}{1 - f_{-}} \left(1 - LE\right)}{1 + \frac{p_{t}\rho}{1 - f_{-}} \left(1 - LE\right)} \frac{1 + \frac{\rho}{f_{-}} \left(1 - p_{t}\right)}{1 + \left(1 - LE\right) \frac{\rho}{f_{-}} \left(1 - p_{t} \left(1 - E\right)\right)} \end{aligned}$$
(S24)

$$\lim_{p_{in} \to 1} \hat{E} = 1 - (1 - E) [1]^{-1} \frac{B + \left[1 + \frac{L}{1 - L} 0\right] (\lambda - R'')}{B + (\lambda - R'' + ER'')} 
= 1 - (1 - E) \left[ 1 + 0 \frac{E \frac{p_t \rho}{1 - f_-}}{1 + \frac{p_t \rho}{1 - f_-} (1 - LE)} \right]^{-1} \frac{1 + \frac{1 - L - LE + L^2 E}{1 - L - LE + L^2 E} \frac{\rho}{f_-} (1 - p_t)}{1 + \frac{1 - L - LE + L^2 E}{f_-} \frac{\rho}{f_-} (1 - p_t)} 
= 1 - (1 - E) \frac{1 + \frac{\rho}{f_-} (1 - p_t)}{1 + \frac{\rho}{f_-} (1 - p_t (1 - E))} 
= 1 - (1 - E) \frac{B + \lambda - R''}{B + \lambda - R'' + ER''} 
= 1 - (1 - E) \frac{1 - \frac{R''}{B + \lambda}}{1 - \frac{R''}{B + \lambda} (1 - E)}$$
(S25)

The final factorization in Eq. S25 shows that, in the limit of perfect alignment of participation and recruitment, the intervention coverage, L, is removed, and the bias depends only on the true efficacy, E, and a combination of epidemiological parameters:  $\frac{R''}{B+\lambda}$ . This relationship can be inverted; which allows us to determine the true efficacy in terms of the estimator value and other parameters:

$$1 - \hat{E} = (1 - E) \frac{1 - \frac{R''}{B + \lambda}}{1 - \frac{R''}{B + \lambda}(1 - E)}$$

$$(1 - \hat{E}) \left(1 - \frac{R''}{B + \lambda}(1 - E)\right) = (1 - E) \left(1 - \frac{R''}{B + \lambda}\right)$$

$$(1 - \hat{E}) = (1 - E) \left[1 - \frac{R''}{B + \lambda} + (1 - \hat{E}) \frac{R''}{B + \lambda}\right]$$

$$(1 - E) = (1 - \hat{E}) \left[1 - \hat{E} \frac{R''}{B + \lambda}\right]^{-1}$$

$$E = 1 - (1 - \hat{E}) \left[1 - \hat{E} \frac{R''}{B + \lambda}\right]^{-1}$$

$$E - \hat{E} = (1 - \hat{E}) \left(1 - \left[1 - \hat{E} \frac{R''}{B + \lambda}\right]^{-1}\right)$$

$$E - \hat{E} = -(1 - \hat{E}) \left(\frac{\hat{E} \frac{R''}{B + \lambda}}{1 - \hat{E} \frac{R''}{B + \lambda}}\right)$$
(S26)

 $\frac{R''}{B+\lambda}$  corresponds to a potentially measurable quantity; recall that in the model, R'' is the expected number of 216 additional test-positives that are identified via the secondary process in a group without the intervention, and 217  $B + \lambda$  is all the other tests (primary negatives and all secondary tests) per primary test-positive. Thus,  $\frac{R''}{B+\lambda}$ 218 is the fraction of secondary test-positives out of all non-index case-finding tests, when measuring in a non-219 intervention group. This value could be estimated from a comparable population without the intervention, 220 or an upper limit could be estimated from data within the study population itself: the expected number 221 of secondary cases in the intervention population is R''(1-LE), so the measured non-primary test-positive 222 fraction would be reduced maximally by a factor (1 - L) when the efficacy is perfect. Note that because 223 this factor only has  $B + \lambda$ , we do not need to distinguish primary versus secondary test-negatives. If a 224 test-negative from  $\lambda$  was mistakenly assigned to B (or vice versa), that would not change this factor. 225

Thus, if a study were able to achieve  $p_{in} \approx 1$ , it only need to be able to distinguish between primary and secondary test-positives to correctly bound the estimator.

### S4.3 Secondary Case Recruitment, $p_t$ , limits 228

If we consider secondary *case* limits, that is what proportion of secondary recruiting is test-positive, then we 229 obtain: 230

$$\lim_{p_t \to 0} \hat{E} = 1 - (1 - E) \left[ 1 + \frac{0}{1 + 0} \frac{L(1 - p_{\rm in})}{1 - Lp_{\rm in}} \right]^{-1} \frac{1 + \frac{1 - Lp_{\rm in} - LEp_{\rm in} + L^2 Ep_{\rm in}}{1 - Lp_{\rm in} - LEp_{\rm in} + L^2 Ep_{\rm in}} \frac{\rho}{f_-}}{1 + \frac{1 - LE}{1 - LEp_{\rm in}} \frac{\rho}{f_-}}$$

$$= 1 - (1 - E) \frac{1 + \frac{1 - Lp_{\rm in} - LEp_{\rm in} + L^2 Ep_{\rm in}}{1 - LEp_{\rm in} + L^2 Ep_{\rm in}^2} \frac{\rho}{f_-}}{1 + \frac{1 - LE}{1 - LEp_{\rm in}} \frac{\rho}{f_-}}}$$

$$\lim_{p_t \to 1} \hat{E} = 1 - (1 - E) \left[ 1 + \frac{E \frac{\rho}{1 - f_-}}{1 + \frac{\rho}{1 - f_-} (1 - LE)} \frac{L(1 - p_{\rm in})}{1 - Lp_{\rm in}} \right]^{-1} \frac{1 + \frac{1 - LEp_{\rm in} - LEp_{\rm in} + L^2 Ep_{\rm in}}{1 + \frac{1 - LEp_{\rm in} + L^2 Ep_{\rm in}^2}{f_-} \frac{\rho}{f_-}}$$

$$= 1 - (1 - E) \left[ 1 + \frac{E \frac{\rho}{1 - f_-}}{1 + \frac{\rho}{1 - f_-} (1 - LE)} \frac{L(1 - p_{\rm in})}{1 - Lp_{\rm in}} \right]^{-1} \frac{1 + \frac{1 - Lep_{\rm in} - LEp_{\rm in} + L^2 Ep_{\rm in}^2}{f_-} \frac{\rho}{f_-} E$$

$$(S27)$$

One way to interpret  $p_t \to 1$  is that transmission probability (conditional on high risk contact) is going up. 231 Another way to think about it is  $\lambda$  coming down to meet R''; *i.e.*, the decision about whether to test a 232 contact or not becoming more accurately linked to whether they were infected. 233

### S4.4 Lower Limit on Secondary Relative Recruiting, $\rho$

234

As primary recruiting increasingly outweighs secondary recruiting (including both increasing primary re-235 cruitment and disallowing secondary recruitment),  $\rho \rightarrow 0$ . In this limit: 236

$$\lim_{\rho \to 0} \hat{E} = 1 - (1 - E) \left[ 1 + \frac{0}{1 + 0} \frac{L(1 - p_{\rm in})}{1 - Lp_{\rm in}} \right]^{-1} \frac{1 + \frac{1 - Lp_{\rm in} - LEp_{\rm in} + L^2 Ep_{\rm in}}{1 - Lp_{\rm in} - LEp_{\rm in} + L^2 Ep_{\rm in}^2} \frac{0}{f_-} (1 - p_t) \\ = 1 - (1 - E) [1]^{-1} \frac{1}{1} = E$$
(S28)

Thus, for sufficiently high rate of primary recruitment leading to test-negatives, the bias goes to 0. 237

### S5Translation of Limits to Recruitment Constraints 238

### Attempting to Limit Recruitment to Participants Only S5.1239

Figures S2-S10 show the general response of the estimator to varying factors in the model. Each plot shows 240  $p_{\text{in}} \in \{0.01, 0.1, 0.25, 0.5, 0.75, 0.9, 1\}$  (columns) and  $p_t \in \{0.01, 0.1, 0.25, 0.5, 0.75, 0.9, 1\}$  (rows). Each plot 241 shows one of the combinations of  $\rho \in \{1/9, 1/3, 1\}$  and  $f_{-} \in \{0.5, 0.75, 0.9\}$ ;  $\rho$  is indicated at the top of each 242 plot,  $f_{-}$  on the right side. 243

These plots show some trends under specific conditions. In general, increasing participation decreases bias 244 range, though not absolutely (e.g.,  $\rho = 1/9, p_t = 1/4, f_- = 0.75$ ). Increasing coverage can shift bias towards 245 underestimation or overestimation, depending  $p_t$ . 246




Figure S2: General Bias Sensitivity, 1 of 9: These series of plots show general sensitivity of the TNCC estimator to all of the model parameters. For each plot, the rightmost column corresponds to very high (99%) participation fraction, which indicates the minimal bias surface when the study manages to maximize participation. Recall,  $\rho = \frac{\lambda}{B+1}$  is the expected ratio of secondary to primary recuits;  $p_t = R''/\lambda$  is the expected fraction of secondary recruits that test positive when no intervention is present; and  $f_- = \frac{B}{B+1}$  is the expect fraction of primary recruits that are test-negative. In this panel,  $\rho = 1/9$  and  $f_- = 0.5$ .




Figure S3: General Bias Sensitivity. 2 of 9: Recall,  $\rho = \frac{\lambda}{B+1}$  is the expected ratio of secondary to primary recuits;  $p_t = R''/\lambda$  is the expected fraction of secondary recruits that test positive when no intervention is present; and  $f_- = \frac{B}{B+1}$  is the expect fraction of primary recruits that are test-negative. In this panel,  $\rho = 1/9$  and  $f_- = 0.75$ .




Figure S4: General Bias Sensitivity. 3 of 9: Recall,  $\rho = \frac{\lambda}{B+1}$  is the expected ratio of secondary to primary recuits;  $p_t = R''/\lambda$  is the expected fraction of secondary recruits that test positive when no intervention is present; and  $f_- = \frac{B}{B+1}$  is the expect fraction of primary recruits that are test-negative. In this panel,  $\rho = 1/9$  and  $f_- = 0.9$ .




Figure S5: General Bias Sensitivity. 4 of 9: Recall,  $\rho = \frac{\lambda}{B+1}$  is the expected ratio of secondary to primary recuits;  $p_t = R''/\lambda$  is the expected fraction of secondary recruits that test positive when no intervention is present; and  $f_- = \frac{B}{B+1}$  is the expect fraction of primary recruits that are test-negative. In this panel,  $\rho = 1/3$  and  $f_- = 0.5$ .




Figure S6: General Bias Sensitivity. 5 of 9: Recall,  $\rho = \frac{\lambda}{B+1}$  is the expected ratio of secondary to primary recuits;  $p_t = R''/\lambda$  is the expected fraction of secondary recruits that test positive when no intervention is present; and  $f_- = \frac{B}{B+1}$  is the expect fraction of primary recruits that are test-negative. In this panel,  $\rho = 1/3$  and  $f_- = 0.75$ .




Figure S7: General Bias Sensitivity. 6 of 9: Recall,  $\rho = \frac{\lambda}{B+1}$  is the expected ratio of secondary to primary recuits;  $p_t = R''/\lambda$  is the expected fraction of secondary recruits that test positive when no intervention is present; and  $f_- = \frac{B}{B+1}$  is the expect fraction of primary recruits that are test-negative. In this panel,  $\rho = 1/3$  and  $f_- = 0.9$ .




Figure S8: **General Bias Sensitivity. 7 of 9**: Recall,  $\rho = \frac{\lambda}{B+1}$  is the expected ratio of secondary to primary recuits;  $p_t = R''/\lambda$  is the expected fraction of secondary recruits that test positive when no intervention is present; and  $f_- = \frac{B}{B+1}$  is the expect fraction of primary recruits that are test-negative. In this panel,  $\rho = 1$  and  $f_- = 0.5$ .




Figure S9: General Bias Sensitivity. 8 of 9: Recall,  $\rho = \frac{\lambda}{B+1}$  is the expected ratio of secondary to primary recuits;  $p_t = R''/\lambda$  is the expected fraction of secondary recruits that test positive when no intervention is present; and  $f_- = \frac{B}{B+1}$  is the expect fraction of primary recruits that are test-negative. In this panel,  $\rho = 1$  and  $f_- = 0.75$ .




Figure S10: General Bias Sensitivity.: Recall,  $\rho = \frac{\lambda}{B+1}$  is the expected ratio of secondary to primary recuits;  $p_t = R''/\lambda$  is the expected fraction of secondary recruits that test positive when no intervention is present; and  $f_- = \frac{B}{B+1}$  is the expect fraction of primary recruits that are test-negative. In this panel,  $\rho = 1$  and  $f_- = 0.9$ .

## <sup>247</sup> S5.2 Attempting to Limit to Primary Recruitment Only

An alternative approach to controlling the bias is to restrict to primary recruitment only. If we assume that the study excludes secondary recruitment perfectly for test-positives (*e.g.* because they are extensively monitored) but incompletely excludes secondary recruitment for test-negatives (*e.g.* because data for them is incomplete) then the full estimator equation:

$$\hat{E} = 1 - (1 - E) \left[ 1 + \frac{E \frac{p_t \rho}{1 - f_-}}{1 + \frac{p_t \rho}{1 - f_-} (1 - LE)} \frac{L(1 - p_{\rm in})}{1 - Lp_{\rm in}} \right]^{-1} \frac{1 + \frac{1 - Lp_{\rm in} - LEp_{\rm in} + L^2 Ep_{\rm in}}{1 - Lp_{\rm in} - LEp_{\rm in} + L^2 Ep_{\rm in}^2 \frac{\rho}{f_-}} (1 - p_t) \frac{1 - Lp_{\rm in}}{1 - Lp_{\rm in} - LEp_{\rm in} - LEp_{\rm in} + L^2 Ep_{\rm in}^2 \frac{\rho}{f_-}} (1 - p_t) \frac{1 - Lp_{\rm in}}{1 - LEp_{\rm in} - LEp_{\rm in} - LEp_{\rm in} - LEp_{\rm in}} \frac{\rho}{f_-} (1 - p_t) \frac{1 - Lp_{\rm in}}{1 - LEp_{\rm in} - LEp_{\rm in} - LEp_{\rm in} + L^2 Ep_{\rm in} \frac{\rho}{f_-}} (1 - p_t) \frac{1 - Lp_{\rm in}}{1 - LEp_{\rm in} - LEp_{\rm in} - LEp_{\rm in} + L^2 Ep_{\rm in} \frac{\rho}{f_-}} \frac{\rho}{f_-} \frac{1 - p_t}{1 - LEp_{\rm in} - LEp_{\rm in} + L^2 Ep_{\rm in} \frac{\rho}{f_-}} \frac{\rho}{f_-} \frac{\rho}{f_-}$$

will lose the test-positive bias contribution, because it goes to 1 (note that for any non-zero  $p_t$ , this term is less than 1):

$$\left[1 + \frac{E\frac{0\rho}{1-f_{-}}}{1 + \frac{0\rho}{1-f_{-}}(1-LE)} \frac{L(1-p_{\rm in})}{1-Lp_{\rm in}}\right]^{-1} = 1$$
(S29)

254 So the overall bias becomes:

$$\hat{E} = 1 - (1 - E) \frac{1 + \frac{1 - L p_{\rm in} - L E p_{\rm in} + L^2 E p_{\rm in}}{1 - L p_{\rm in} - L E p_{\rm in} + L^2 E p_{\rm in}^2} \frac{\beta \rho}{f_-} (1 - p_t)}{1 + \frac{1 - L E}{1 - L E p_{\rm in}} \frac{\beta \rho}{f_-} (1 - p_t (1 - E))}$$
(S30)

where  $\beta \in (0, 1)$  is the exclusion failure probability;  $\beta = 0$  is perfect exclusion of secondary test-negatives (in which case the test-negative term also reduces to 1) while  $\beta = 1$  implies that no secondary test-negatives are excluded. Note that this factor is simply reducing  $\rho$  in the test-negative odds term. Thus, we can drop  $\beta$ and instead reduce the range we consider for  $\rho$ . The error expression for this scenario is:

$$\begin{split} E - \hat{E} &= E - 1 + (1 - E) \frac{1 + \frac{1 - Lp_{in} - LEp_{in} + L^2 Ep_{in}^2}{1 + \frac{1 - Lp_{in} - LEp_{in} + L^2 Ep_{in}^2}{1 - p_t} \frac{f}{p_t} (1 - p_t)}{1 + \frac{1 - LE}{1 - LEp_{in} + L^2 Ep_{in}^2} \frac{f}{p_t} (1 - p_t)} \\ &= -(1 - E) \left[ 1 - \frac{1 + \frac{1 - Lp_{in} - LEp_{in} + L^2 Ep_{in}^2}{1 + \frac{1 - LE}{1 - LEp_{in} + L^2 Ep_{in}^2} \frac{f}{p_t} (1 - p_t)}}{1 + \frac{1 - LE}{1 - LEp_{in} - LEp_{in} + L^2 Ep_{in}^2} \frac{f}{p_t} (1 - p_t)} \right] \\ &= -(1 - E) \left[ \frac{\frac{1 - LE}{1 - LEp_{in} - LEp_{in} + L^2 Ep_{in}^2} \frac{f}{p_t} (1 - p_t (1 - E))}{1 + \frac{1 - LE}{1 - LEp_{in} - LEp_{in} + L^2 Ep_{in}^2} \frac{f}{p_t} (1 - p_t)}} \right] \\ &= -(1 - E) \left[ \frac{\frac{1 - LE}{1 - LEp_{in} f_{-}} (1 - p_t (1 - E)) - \frac{1 - Lp_{in} - LEp_{in} + L^2 Ep_{in}^2}{1 - p_{in} - LEp_{in} + L^2 Ep_{in}^2} \frac{f}{p_t} (1 - p_t)} \right] \\ &= \frac{-(1 - E) \frac{f}{f_{-}}}{(1 - Lp_{in})} \frac{(1 - Lp_{in} (1 - LE)(1 - p_t (1 - E)) - (1 - Lp_{in} - LEp_{in} + L^2 Ep_{in})(1 - p_t)}{(1 - LEp_{in}) + (1 - LE) \frac{f}{f_{-}} (1 - p_t (1 - E))} \\ &= \frac{-(1 - E) \frac{f}{f_{-}}}{(1 - Lp_{in})} \frac{(1 - Lp_{in} - LE + L^2 Ep_{in})(1 - p_t (1 - E)) - (1 - Lp_{in} - LEp_{in} + L^2 Ep_{in})(1 - p_t)}{(1 - LEp_{in}) + (1 - LE) \frac{f}{f_{-}} (1 - p_t (1 - E))} \\ &= \frac{-(1 - E) \frac{f}{f_{-}}}{(1 - Lp_{in})} \frac{(1 - Lp_{in} - LE + L^2 Ep_{in})(1 - p_t (1 - E)) - (1 - Lp_{in} - LEp_{in} + L^2 Ep_{in})(1 - p_t)}{(1 - LEp_{in}) + (1 - LE) \frac{f}{f_{-}} (1 - p_t (1 - E))} \\ &= \frac{-(1 - E) \frac{f}{f_{-}}}{(1 - Lp_{in})} \frac{(1 - Lp_{in} - LE + L^2 Ep_{in})Ep_t - LE(1 - p_t) + LEp_{in} (1 - p_t)}{(1 - LEp_{in}) + (1 - LE) \frac{f}{f_{-}} (1 - p_t (1 - E))} \\ &= \frac{-(1 - E) \frac{f}{f_{-}}}{(1 - Lp_{in})} \frac{(1 - Lp_{in} - LE + L^2 Ep_{in})Ep_t - LE(1 - p_t)(1 - p_{in})}{(1 - LEp_{in}) + (1 - LE) \frac{f}{f_{-}} (1 - p_t (1 - E))} \\ &= \frac{-(1 - E) \frac{f}{f_{-}}}}{(1 - Lp_{in})} \frac{(1 - Lp_{in} - LE + L^2 Ep_{in})Ep_t - LE(1 - p_t)(1 - p_{in})}{(1 - LEp_{in}) + (1 - LE) \frac{f}{f_{-}} (1 - p_t (1 - E))} \\ &= \frac{-(1 - E) \frac{E}{f_{-}}}}{(1 - Lp_{in})} \frac{(1 - Lp_{in})(1 - LE)p_t - L(1 - p_{in})(1 - p_{in})}{(1 - LEp_{in}) + (1 - LE) \frac{f}{f_{-}} (1 - p_$$

Because  $p_{in}$  remains in the equation, in multiple places, the participating fraction plays an important role in bias. If participation is high, and for the case of  $p_{in} \rightarrow 1$ , then we can then recover:

$$\lim_{p_{\text{in}} \to 1} E - \hat{E} = \frac{-(1-E)E\frac{\rho}{f_{-}}}{(1-L)} \frac{(1-L)(1-LE)p_{t} - L(1-p_{t})(1-1)}{(1-LE) + (1-LE)\frac{\rho}{f_{-}}(1-p_{t}(1-E))}$$
$$= -(1-E)E\frac{\rho}{f_{-}}\frac{p_{t}}{1+\frac{\rho}{f_{-}}(1-p_{t}(1-E))}$$
$$= -(1-E)E\frac{p_{t}}{1+\frac{f_{-}}{\rho} - p_{t}(1-E))}$$
(S32)

which is the same error as if we had just been able to control  $p_{in} \rightarrow 1$ . This suggests that if the study could mostly manage heterogeneity in the recruited population, but likely could not exclude secondary test-negatives, then including all secondary cases does not affect the magnitude of bias.

Figures S11-S19 show the response of the estimator to varying factors when secondary testpositives are excluded. Each plot shows  $p_{\text{in}} \in \{0.01, 0.1, 0.25, 0.5, 0.75, 0.9, 1\}$  (columns) and  $p_t \in \{0.01, 0.1, 0.25, 0.5, 0.75, 0.9, 1\}$  (rows). Each plot shows one of the combinations of  $\rho \in \{1/9, 1/3, 1\}$  and  $f_- \in \{0.5, 0.75, 0.9\}$ ;  $\rho$  is indicated at the top of each plot,  $f_-$  on the right side.

In general, these plots show the same trends as Figures S2-S10, with lower bias magnitude and tendency to shift towards underestimation.




Figure S11: Bias Sensitivity Without Secondary Test-Positives, 1 of 9: These series of plots show sensitivity of the TNCC estimator which excludes secondary test-positives to all of the model parameters. For each plot, the rightmost column corresponds to very high (99%) participation fraction, which indicates the minimal bias surface when the study manages to maximize participation. Recall,  $\rho = \frac{\lambda}{B+1}$  is the expected ratio of secondary to primary recuits;  $p_t = R''/\lambda$  is the expected fraction of secondary recruits that test positive when no intervention is present; and  $f_- = \frac{B}{B+1}$  is the expect fraction of primary recruits that are test-negative. In this panel,  $\rho = 1/9$  and  $f_- = 0.5$ .




Figure S12: Bias Sensitivity Without Secondary Test-Positives. 2 of 9: Recall,  $\rho = \frac{\lambda}{B+1}$  is the expected ratio of secondary to primary recuits;  $p_t = R''/\lambda$  is the expected fraction of secondary recruits that test positive when no intervention is present; and  $f_- = \frac{B}{B+1}$  is the expect fraction of primary recruits that are test-negative. In this panel,  $\rho = 1/9$  and  $f_- = 0.75$ .




Figure S13: Bias Sensitivity Without Secondary Test-Positives. 3 of 9: Recall,  $\rho = \frac{\lambda}{B+1}$  is the expected ratio of secondary to primary recuits;  $p_t = R''/\lambda$  is the expected fraction of secondary recruits that test positive when no intervention is present; and  $f_- = \frac{B}{B+1}$  is the expect fraction of primary recruits that are test-negative. In this panel,  $\rho = 1/9$  and  $f_- = 0.9$ .




Figure S14: Bias Sensitivity Without Secondary Test-Positives. 4 of 9: Recall,  $\rho = \frac{\lambda}{B+1}$  is the expected ratio of secondary to primary recuits;  $p_t = R''/\lambda$  is the expected fraction of secondary recruits that test positive when no intervention is present; and  $f_- = \frac{B}{B+1}$  is the expect fraction of primary recruits that are test-negative. In this panel,  $\rho = 1/3$  and  $f_- = 0.5$ .




Figure S15: Bias Sensitivity Without Secondary Test-Positives. 5 of 9: Recall,  $\rho = \frac{\lambda}{B+1}$  is the expected ratio of secondary to primary recuits;  $p_t = R''/\lambda$  is the expected fraction of secondary recruits that test positive when no intervention is present; and  $f_- = \frac{B}{B+1}$  is the expect fraction of primary recruits that are test-negative. In this panel,  $\rho = 1/3$  and  $f_- = 0.75$ .




Figure S16: Bias Sensitivity Without Secondary Test-Positives. 6 of 9: Recall,  $\rho = \frac{\lambda}{B+1}$  is the expected ratio of secondary to primary recuits;  $p_t = R''/\lambda$  is the expected fraction of secondary recruits that test positive when no intervention is present; and  $f_- = \frac{B}{B+1}$  is the expect fraction of primary recruits that are test-negative. In this panel,  $\rho = 1/3$  and  $f_- = 0.9$ .




Figure S17: Bias Sensitivity Without Secondary Test-Positives. 7 of 9: Recall,  $\rho = \frac{\lambda}{B+1}$  is the expected ratio of secondary to primary recuits;  $p_t = R''/\lambda$  is the expected fraction of secondary recruits that test positive when no intervention is present; and  $f_- = \frac{B}{B+1}$  is the expect fraction of primary recruits that are test-negative. In this panel,  $\rho = 1$  and  $f_- = 0.5$ .




Figure S18: Bias Sensitivity Without Secondary Test-Positives. 8 of 9: Recall,  $\rho = \frac{\lambda}{B+1}$  is the expected ratio of secondary to primary recuits;  $p_t = R''/\lambda$  is the expected fraction of secondary recruits that test positive when no intervention is present; and  $f_- = \frac{B}{B+1}$  is the expect fraction of primary recruits that are test-negative. In this panel,  $\rho = 1$  and  $f_- = 0.75$ .




Figure S19: Bias Sensitivity Without Secondary Test-Positives.: Recall,  $\rho = \frac{\lambda}{B+1}$  is the expected ratio of secondary to primary recuits;  $p_t = R''/\lambda$  is the expected fraction of secondary recruits that test positive when no intervention is present; and  $f_- = \frac{B}{B+1}$  is the expect fraction of primary recruits that are test-negative. In this panel,  $\rho = 1$  and  $f_- = 0.9$ .

## <sup>270</sup> S6 Calculation of Coverage, L, and Participation, $p_{in}$

In addition to parameters associated with epidemiology and response activities  $(B, \lambda, and R'')$ , the values of L 271 and  $p_{in}$  are required to determine what level of bias may be present. Our model proposes a population where 272 there are three groups, non-participators, and participators that receive the intervention or not. If we have 273 an estimate for the size of the total recruitable population, we can use measures taken during the intervention 274 distribution to estimate these values. Alternatively, additional data could be collected when testing recruits 275 to estimate these values. The estimates proposed hereafter are not definitive; in addition to assuming our 276 model of heterogeneity is a sufficiently useful approximation, they make further strong assumptions about 277 behaviour around intervention uptake. However, as estimates they are potentially informative about the 278 limits of  $p_{in}$  and L within the model framework we have proposed. 279

## 280 S6.1 Measures During Intervention Distribution

<sup>281</sup> During distribution of the intervention, one could count the number of people receiving the intervention <sup>282</sup> (V) and the number ineligible (U\*). From those values we can compute the crude minimum and maximum <sup>283</sup> values of L and  $p_{in}$  (where max(L) corresponds to min( $p_{in}$ ), and vice versa).

$$L \in \left(\frac{V}{T}, \frac{V}{V + U*}\right)$$
$$p_{\text{in}} \in \left(0, 1 - \frac{V + U*}{T}\right)$$
(S33)

In the model, we make no assumptions of how non-intervention occurs in the participating population, just that it occurs randomly within that group. Thus the ineligible count represents the minimum nonintervention amongst the participating population (the upper limit of L); there may be other sources (*e.g.*, participants are unavailable on the day offered). Potentially, when distributing the intervention, participants could be asked about members of their household, neighbors, *etc.* that wanted to get the intervention, but were unable to do so, but this number would also have many uncertainties (*e.g.* duplicate reporting, reporting individuals that do receive the intervention at a different time or place).

If the study intervention has multiple steps (e.g. a two-dose vaccine, repeat application of vector-control291 insecticides), then the decrease in coverage between steps could be informative about the participation rate, 292  $p_{\text{in}}$ . If we assume not receiving the intervention is due to a mix of short-term (e.g. ill that day) and long-term 293 (e.g. too young to be eligible) effects, then we can potentially further constrain L and  $p_{\rm in}$ . In the following 294 we assume that: i) long-term ineligibles only present themselves at the first step (though they may also 295 not), ii) short-term ineligibles present at the same rate in the subsequent steps, and iii) individuals that 296 did not present at earlier steps will also not present later. If we apply these assumptions to a two-step 297 intervention, and we call unobserved long-term ineligibles  $I_0$ , the long-term ineligibles that appear initially 298 are  $I_1$ , and the intervention recipients (V) and short-term ineligibles that present (U<sup>\*</sup>) or not (U) at each 299 stage  $(V_1, V_2, U_{*1}, U_{*2}, U_1, U_2)$ , then the following relations hold. 300

We have six observed pieces of information: the total population (T), the number given the intervention versus short term ineligible at both steps  $(V_1, V_2, U_{*1}, U_{*2})$ , and the number of long-term ineligibles at the first step  $(I_1)$ .

<sup>304</sup> We know that at the second intervention step, we have only people that got vaccinated in the previous step,

no new long term ineligibles, and the breakdown of short term ineligibles versus those that receive the second
 step. So:

$$V_1 = U_2 + U_2^* + V_2 \implies U_2 = V_1 - V_2 - U_2^*$$
(S34)

<sup>307</sup> If we assume that the division between presenting versus not presenting for short-term ineligibles is the same
 <sup>308</sup> for both steps, then:

$$\frac{U_2^*}{U_2 + U_2^*} = \frac{U_1^*}{U_1 + U_1 *} \implies \frac{U_2^*}{U_2 + U_2^*} (U_1 + U_1 *) = U_1^* 
\implies \frac{U_2^*}{U_2 + U_2^*} U_1 = U_1^* \left( 1 - \frac{U_2^*}{U_2 + U_2^*} \right) 
\implies U_1^* \frac{V_1 - V_2 - U_2^*}{U_2^*} = U_1$$
(S35)

For the first distribution of the intervention, we assume that the ratio of short- and long-term ineligibles presenting is the same as those not presenting:

$$\frac{U_1^*}{U_1^* + I_1} = \frac{U_1}{U_1 + I_0} \implies \frac{U_1^*}{U_1^* + I_1} (U_1 + I_0) = U_1$$

$$\implies \frac{U_1^*}{U_1^* + I_1} I_0 = U_1 \left( 1 - \frac{U_1^*}{U_1^* + I_1} \right)$$

$$\implies I_0 = U_1 \frac{I_1}{U_1^*} = I_1 \frac{V_1 - V_2 - U_2^*}{U_2^*}$$
(S36)

<sup>311</sup> Finally, the pieces must add up to the total population, and therefore:

$$C = V_{1} + U_{1}^{*} + I_{1} + U_{1} + I_{0}$$

$$= V_{1} + U_{1}^{*} \left( 1 + \frac{V_{1} - V_{2} - U_{2}^{*}}{U_{2}^{*}} \right) + I_{1} \left( 1 + \frac{V_{1} - V_{2} - U_{2}^{*}}{U_{2}^{*}} \right)$$

$$= V_{1} + \frac{V_{1} - V_{2}}{U_{2}^{*}} \left( U_{1}^{*} + I_{1} \right)$$

$$T = C + N$$

$$N = T - C$$

$$= T - V_{1} - \frac{V_{1} - V_{2}}{U_{2}^{*}} \left( U_{1}^{*} + I_{1} \right)$$
(S37)

<sup>312</sup> So using these assumptions, we can estimate the coverage and the participating fraction:

$$L = \frac{V}{C} = \frac{V_2}{V_1 + \frac{V_1 - V_2}{U_2^*} (U_1^* + I_1)}$$

$$p_{\rm in} = \frac{C}{T} = \frac{V_1 + \frac{V_1 - V_2}{U_2^*} (U_1^* + I_1)}{T}$$
(S38)

Both of these equations consist only of the measured values. Since the model is an approximation, there may be other effects, but these relations can provide a useful guide to the value of the study parameters that contribute to bias.

## 316 S7 Alternative Scenario Translation

In the main text, we described applying this model to evaluating a novel vaccine during an Ebola outbreak, but noted in the discussion that the approach could be generically applicable. The previous sections outline the model in generic terms. Here we provide an example translation of that generalisation to another case: a vector control intervention for dengue.

In this scenario, we consider an intervention like indoor residual spraying, applied to urban households on a block basis (*i.e.* set of contiguous households, determined by street intersections) ahead of the dengue season. Some blocks would get no coverage (*i.e.* be amongst the non-participating population), while others would receive coverage at some level (with non-coverage corresponding to *e.g.* availability to let treatment teams into house on that day or presence of shildren under some age)

teams into house on that day or presence of children under some age).

Later, during the dengue season, people in the study population would seek healthcare with symptoms that

327 would lead to testing for dengue, corresponding to the primary process. However, because dengue is fre-

quently asymptomatic, the secondary process would be to test individuals in the primary cases household and

<sup>329</sup> adjacent households. Instead of a contacts-based secondary route, there is geospatial secondary route.

<sup>330</sup> Whether a TNCC study would be ideal for this scenario is certainly a topic for debate. However, it is possible

<sup>331</sup> to frame this scenario and other potential pathogen spread and surveillance processes in the same terms we

<sup>332</sup> have introduced in this analysis.